Pomona, New York — May 8, 2025 — NeuroLight, Inc. is pleased to announce the appointment of Kai Peterson as our new Director of Non-dilutive Funding and Grants.
Kai brings over 12 years of specialized experience in securing non-dilutive financing for healthcare and biotech companies, with a proven track record of obtaining grants from organizations including the Department of Defense, National Institutes of Health, and BARDA.
With an M.S. in Biomedical Engineering from California Polytechnic State University (Cal Poly), Kai’s background includes extensive experience in medical writing, technical documentation, FDA submissions, grant proposal development, and clinical project management. His expertise spans multiple therapeutic areas including neuromuscular disease, and ocular regeneration.
“We are thrilled to welcome Kai to the NeuroLight team,” said Alexander Poltorak, Founder and President of NeuroLight. “His extensive experience in securing government funding and managing complex development programs will be instrumental as we advance our innovative neuromodulation technologies for treating sleep and CNS conditions. Kai’s background in biomedical engineering and his proven ability to translate complex scientific concepts into compelling grant proposals make him the perfect fit for this crucial role.”
At NeuroLight, Kai will lead our non-dilutive funding strategy, identifying and securing government grants and other non-dilutive funding opportunities to accelerate the development of our groundbreaking neuromodulation technologies. NeuroLight was previously awarded Phase I NSF/SBIR Grant. Its innovative technology is protected by 11 US issued patents and pending applications abroad.
Please join us in welcoming Kai Peterson to the NeuroLight family as we continue our mission to revolutionize the treatment of insomnia, prevention of Alzheimer’s disease, dementias and improving longevity through sensory brain stimulation.
